Castle Biosciences CSTL 深 沪
已收盘 05-15 16:00:00 美东时间
19.13
+0.250
+1.32%
华盛通- 最 高19.61
- 今 开18.69
- 成交量 55.49万股
- 最 低 18.635
- 昨 收 18.88
- 总市值 5.80亿
- 52周最高 44.28
- 市盈率 静 --
- 换手率 1.83%
- 52周最低 14.59
- 委 比 93.36%
- 总股本 3029.60万
- 历史最高 107.69
- 量 比 0.92
- 振 幅 5.16%
- 历史最低 9.2601
- 每 手 1
- 风险率 7.98%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 潜在涨幅257.14%！瑞杰金融上调InflaRx目标价至9美元，评级升至"强烈买入"
今日重点评级关注：瑞杰金融：上调InflaRx评级至"强烈买入"，目标价从7美元升至9美元；巴克莱：维持Orchestra BioMed Hldgs"超配"评级，目标价从12美元升至13美元
05-14 14:32
BTIG Maintains Buy on Castle Biosciences, Lowers Price Target to $40
BTIG analyst Mark Massaro maintains Castle Biosciences (NASDAQ:CSTL) with a Buy and lowers the price target from $50 to $40.
05-13 17:48
U.S. RESEARCH ROUNDUP-Aecom, Humana, Mosaic
U.S. RESEARCH ROUNDUP-Aecom, Humana, Mosaic May 13 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Aecom, Humana and Mosaic on Wednesday. HIGHLIGHTS * Aecom ACM.N : RBC cuts target price to $111 from $142 * Humana HUM.N
05-13 15:31
Earnings Scheduled For May 6, 2026
Companies Reporting Before The Bell • Deluxe (NYSE:DLX) is expected to report q...
05-07 05:03
美股大行评级 | 大摩上调Lumentum目标价从595美元升至710美元；康宁、道富银行、Ally Financial获多家机构上调目标价
今日重点评级关注：Canaccord Genuity：维持Vertical Aerospace"买入"评级，目标价从9.5美元升至10.5美元；Canaccord Genuity：维持AtaiBeckley Inc."买入"评级，目标价从14美元升至15美元
04-21 11:25
Canaccord Genuity Maintains Buy on Castle Biosciences, Lowers Price Target to $40
Canaccord Genuity analyst Kyle Mikson maintains Castle Biosciences (NASDAQ:CSTL) with a Buy and lowers the price target from $50 to $40.
04-21 00:12
Castle Biosciences To Present New Data Showing DecisionDx-Melanoma Test Refines Mortality Risk Within AJCC Stages For Patients With Cutaneous Melanoma At 2026 AAD Annual Meeting
Data from 1,868 Surveillance, Epidemiology and End Results (SEER)-linked patients show DecisionDx-Melanoma significantly stratifies five-year melanoma-specific survival within American Joint Committee on Cancer (AJCC)
03-27 21:08
Castle Biosciences shares rise; DecisionDx-Melanoma study in 1,868 SEER-linked patients shows 5-year melanoma-specific survival of 96.7% for Class 1A vs 70.0% for Class 2B in T1 tumors
Castle Biosciences shares rise; DecisionDx-Melanoma study in 1,868 SEER-linked patients shows 5-year melanoma-specific survival of 96.7% for Class 1A vs 70.0% for Class 2B in T1 tumors Castle announced an analysis of 1,868 SEER-linked patients with stage I–III cutaneous melanoma evaluating its Decis
03-27 21:07
Sweden's SciBase Q4 sales rise on US, skin barrier growth
Sweden's SciBase Q4 sales rise on US, skin barrier growth Overview Sweden medical technology firm's Q4 net sales rose 45% yr/yr, loss after tax widened Gross margin fell to 63% from 68.5%, impacted by currency and higher input costs Outlook Company did not provide specific financial or operational g
03-13 15:13
Castle Biosciences' i31‑SLNB Test Validates Predictive Accuracy In Melanoma Study, Supports Safe SLNB Avoidance
Study results were recently shared at the Society of Surgical Oncology (SSO) 2026 Annual Meeting in Phoenix.NCCN Cutaneous Melanoma Guidelines recommend avoiding a sentinel lymph node (SLN) biopsy (SLNB) if the
03-09 19:12
